Tag: typhoid vi polysaccharide vaccine market growth

  • Typhoid Vi Polysaccharide Vaccine Market Growth Potential: Key Insights for 2024-2033

    Typhoid Vi Polysaccharide Vaccine Market Growth Potential: Key Insights for 2024-2033

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    How Will the Typhoid Vi Polysaccharide Vaccine Market Grow from 2024 to 2033?

    Rapid growth has been observed in recent years in the typhoid vi polysaccharide vaccine market size. It is projected to expand from $4.98 billion in 2023 to $5.84 billion in 2024, demonstrating a compound annual growth rate (CAGR) of 17.3%. The historic period’s growth is credited to factors such as disease prevalence, international health drives, vaccinations for travelers, government-led immunization programs, and the efficacy and safety of the vaccine.

    In the coming years, the market for the typhoid vi polysaccharide vaccine is projected to experience swift expansion. By 2028, it is anticipated to escalate to $11.28 billion, at a compound annual growth rate (CAGR) of 17.9%. The surge during the forecast period can be credited to the broadening of immunization agendas, increased focus on global health policy, epidemiological surveillance, an uptick in demand regarding travel medicine, along with environmental and societal influences. Key trend predictions during the forecast period encompass research and development investments, administrative backing, epidemiological research, and an increase in public health consciousness.

    Claim Your Free Sample of the Global Typhoid Vi Polysaccharide Vaccine Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

    What Aspects Are Influencing the Growth Rate of the typhoid vi polysaccharide vaccine Market?

    An increase in the incidence of typhoid is anticipated to fuel the development of the typhoid VI polysaccharide vaccine market in the future. Typhoid, a potentially lethal infection, is caused by the bacteria Salmonella typhi and it generally transmits via contaminated food or beverages. The typhoid Vi polysaccharide vaccine is utilized to protect adults and children aged 2 years and older from typhoid fever induced by Salmonella enterica serovar Typhi, or S. Typhi. As per a report published by the Centers for Disease Control and Prevention (CDC) – a US-based national public health agency – in March 2021, it was assumed that around 5,700 Americans were affected annually by Salmonella Typhi, with approximately 620 needing hospital care. With 11 to 21 million cases globally and 200,000 deaths annually, typhoid fever is prevalent, thereby stimulating the advancement of the typhoid Vi polysaccharide vaccine market.

    What Key Segments Exist Within the Typhoid Vi Polysaccharide Vaccine Market?

    The typhoid vi polysaccharide vaccine market covered in this report is segmented –

    1) By Type: Child, Adult

    2) By Route of Administration: Oral, Parenteral

    3) By Application: Government Institution, Private Sector, Other Applications

    What Trends Are Redefining Consumer Expectations in the Typhoid Vi Polysaccharide Vaccine Market?

    Forming strategic alliances is becoming increasingly trendy in the typhoid Vi polysaccharide vaccine industry. Major firms in this sector are entering into collaborations to boost their standing in the typhoid Vi polysaccharide market. Example of this is the partnership between The International Vaccine Institute, a South Korea-based international organization dedicated to addressing global health concerns like cholera, typhoid, shigella, and salmonella, and Moderna, a biopharmaceutical company based in the United States, in July 2022. This collaboration resulted in the creation of the world’s first cost-friendly oral cholera vaccine and a novel typhoid conjugate vaccine.

    Order Now for Fast Delivery of Your Typhoid Vi Polysaccharide Vaccine Market Report!

    https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

    What Are the Leading Regions in the Typhoid Vi Polysaccharide Vaccine Market Expansion?

    Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2023. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    The Typhoid Vi Polysaccharide Vaccine Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the typhoid vi polysaccharide vaccine market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Typhoid Vi Polysaccharide Vaccine Market Include

    1. Typhoid Vi Polysaccharide Vaccine Market Executive Summary

    2. Typhoid Vi Polysaccharide Vaccine Market Segments

    3. Typhoid Vi Polysaccharide Vaccine Market Size And Template Market Growth Rate

    4. Key Typhoid Vi Polysaccharide Vaccine Market Trends

    5. Major Typhoid Vi Polysaccharide Vaccine Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Typhoid Vi Polysaccharide Vaccine Market

    26. Top Typhoid Vi Polysaccharide Vaccine Companies

    27. Typhoid Vi Polysaccharide Vaccine Market Opportunities And Strategies

    28. Typhoid Vi Polysaccharide Vaccine Market, Conclusions And Recommendations

    29. Appendix

    Discover Related Reports by The Business Research Company:

    Vaccine Contract Manufacturing Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    Cancer Diagnostics Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Optical Wavelength Services Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/optical-wavelength-services-global-market-report

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Global Typhoid Vi Polysaccharide Vaccine Market Key Insights 2024-2033

    Global Typhoid Vi Polysaccharide Vaccine Market Key Insights 2024-2033

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

    According to The Business Research Company’s Typhoid Vi Polysaccharide Vaccine Global Market Report 2024, the typhoid Vi polysaccharide vaccine market is expected to show promising growth in the forecast period.

    The typhoid Vi polysaccharide vaccine market size has experienced significant expansion in recent years, with projections indicating continued growth into the foreseeable future.

    Market Size and Growth Trends

    • The market is estimated to have reached $4.98 billion in 2023 and is forecasted to grow to $5.84 billion in 2024, reflecting a compound annual growth rate (CAGR) of 17.3%.
    • Projections suggest that by 2028, the market will soar to $11.28 billion, at a CAGR of 17.9%.
    • Factors contributing to this growth include disease prevalence, global health initiatives, traveler vaccination, government immunization efforts, and vaccine efficacy and safety.

    Factors Driving Market Expansion

    Escalating Typhoid Prevalence Fuels Expansion in the Typhoid Vi Polysaccharide Vaccine Market

    • Typhoid fever, caused by Salmonella typhi, remains a significant global health concern.
    • The disease spreads through contaminated food or drink and poses severe health risks.
    • The CDC estimates approximately 5,700 Americans are infected with Salmonella Typhi annually, with a considerable number requiring hospitalization.
    • Worldwide, typhoid fever contributes to between 11 and 21 million cases annually, resulting in 200,000 fatalities.
    • Rising prevalence is a primary driver of the market’s growth trajectory.

    Healthcare Expenditure Surge Fuels Growth in the Typhoid Vi Polysaccharide Vaccine Market

    • Increasing investments in healthcare infrastructure worldwide are bolstering market expansion.
    • Healthcare expenditure, including both public and private spending, is rising as a percentage of GDP.
    • The USA’s National Health Expenditure Projections indicate significant growth, with healthcare spending expected to reach nearly $6.0 trillion by 2027.
    • This surge in expenditure supports the development and distribution of typhoid Vi polysaccharide vaccines, driving market growth.

    View More On The Typhoid Vi Polysaccharide Vaccine Market Report 2024 – https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

    Market Players and Innovations

    Innovative Collaborations and Strategic Investments in Typhoid Vi Polysaccharide Vaccine Development

    • Major players in the market are actively investing in research and development to strengthen their market presence.
    • Notable collaborations include SK Bioscience and Vaxxas, who secured funding to develop a typhoid conjugate vaccine.
    • This partnership aims to utilize Vaxxas’ needle-free vaccination technology to enhance vaccine delivery efficiency.

    Market Segmentation and Regional Insights

    Segmentation Insights

    • The typhoid vi polysaccharide vaccine market is segmented based on type (child, adult), route of administration (oral, parenteral), and application (government institution, private sector, other applications).

    Regional Dominance

    • Asia-Pacific emerged as the largest region in the typhoid Vi polysaccharide vaccine market share in 2023.
    • This underscores the region’s significant role in driving market growth and addressing public health challenges.

    Conclusion: Toward a Healthier Future

    The rapid expansion of the typhoid Vi polysaccharide vaccine market reflects global efforts to combat infectious diseases and improve public health outcomes. With escalating typhoid prevalence and increased healthcare spending, stakeholders must continue to prioritize research, innovation, and collaboration to meet evolving healthcare needs. As the market continues to evolve, investments in vaccine development, regulatory support, and public health awareness will be instrumental in shaping a healthier future for communities worldwide.

    Request A Sample Of The Global Typhoid Vi Polysaccharide Vaccine Market Report 2024:
    https://www.thebusinessresearchcompany.com/sample_request?id=8313&type=smp